Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol MyersBristol-Myers SquibbandJohnson & JohnsonU.S. healthcare giants with distinct development strategies: the former focuses primarily on biopharmaceuticals, while the latter adopts a broad operational model encompassing both pharmaceuticals and medical devices.

Key Data: Bristol Myers Squibb reported revenue of $48.2 billion in fiscal year 2025, a slight decrease of 0.2% from the previous year; Johnson & Johnson reported revenue of $94.2 billion for the same period, a year-over-year increase of 6.0%.

Both companies offer critical healthcare solutions and maintain stable dividend payouts, making them core holdings for conservative investors.

The translated content is provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express